In a significant move within the pharmaceuticals industry, German vaccine manufacturer BioNTech has completed the acquisition of its domestic rival CureVac. The all-stock takeover, valued at approximately $1.25 billion, marks a continuation of BioNTech’s strategic expansion into cancer treatment, following its recent $11 billion partnership with US-based Bristol Myers Squibb. Legal advice for this transaction was provided by high-profile international law firms, including Covington & Burling LLP, Hengeler Mueller, Skadden, Arps, Slate, Meagher & Flom LLP, and Latham & Watkins LLP.
For further details on the legal intricacies of the deal, you can read the full article on Law.com.